• Provides three separate results to optimize treatment for patients with breast cancer
  • Greater prognostic value compared to first generation tests in both node-negative and node-positive disease1
  • Safely moves more patients to low risk avoiding costly chemotherapy1

    Fact Sheets and Product Info:

    Executive Summary Download PDF
    Tech Specifications View Info
    Clinical Dossier Download PDF
    Digital Dossier View Dossier


    About Breast Cancer:

    Breast cancer is the second most common cancer in women after skin cancer. In 2020, it is estimated that there will be 276,480 new cases of female breast cancer and an estimated 42,170 people will die of this disease.2


    About EndoPredict:

    EndoPredict (EPclin), a breast cancer prognostic test, analyzes RNA expression of 8 target genes, 3 normalization genes, and 1 control gene, creating a 12-gene molecular score, which is then combined with clinical features of the tumor (tumor size and nodal status) to predict the 10-year distant recurrence (DR) rate. This information may be used by treating physicians to guide therapy decisions by identifying which patients have sufficiently low risk of DR and may safely forgo chemotherapy, and which patients are at high risk for DR and may need adjuvant chemotherapy in addition to endocrine therapy.


    1. Sestak I, Buus R, Cuzick J, et al. JAMA Oncol. 2018 Feb;4(4):545-553.
    2. National Cancer Institute. Retrieved September 2020 from: https://seer.cancer.gov/statfacts/html/breast.html.

    Myriad Products